A menopause society has issued guidance on GLP-1 use, and it is candid about the evidence gap

A menopause society has issued guidance on GLP-1 use, and it is candid about the evidence gap

The Spanish Menopause Society published an expert position statement on 25 August covering the use of GLP-1 and dual incretin medications in peri- and postmenopausal women with overweight or obesity. It sets out 20 positions across body composition, cardiometabolic risk, musculoskeletal health, monitoring and interaction with hormone therapy. The most useful thing in it, for … Read more

Semaglutide cut inflammation as well as weight in a review of nine trials

Semaglutide cut inflammation as well as weight in a review of nine trials

A systematic review and meta-analysis published on 29 August pooled nine randomised trials covering 6,239 adults with overweight or obesity but without diabetes, and found that injected semaglutide reduced a standard marker of inflammation by roughly 40% alongside the weight loss it is prescribed for. Serious adverse events were no more common than on placebo. … Read more